Phase IIa trial of IDX 719 + simeprevir + ritonavir-boosted TMC 647055 with or without ribavirin for treatment-naive patients with hepatitis C infection (HELIX-2)
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Samatasvir (Primary) ; Simeprevir (Primary) ; TMC 647055 (Primary) ; Ribavirin; Ritonavir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms HELIX-2
- 01 May 2014 According to an Idenix Pharmaceuticals media release, sustained virological response rate (SVR4) data will be reported in the second-half of 2014.
- 02 Dec 2013 Idenix MR, same as 9156943.
- 02 Dec 2013 Status changed from planning to recruiting, according to a Medivir AB media release.